Morphine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Morphine: From Moderate-to-Severe Pain to Myofascial Pain Syndrome
One-Sentence Summary
Morphine is a mu-opioid receptor full agonist classically used for moderate-to-severe pain (analgesia). The TxGNN model predicts it may be effective for Myofascial Pain Syndrome, with 33 clinical trials and 17 publications identified in the surrounding evidence base — but none of them directly test morphine as a treatment for myofascial pain syndrome itself, so this signal should be read as a mechanistic hypothesis rather than clinical proof.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Moderate-to-severe pain (opioid analgesia) — general pharmacological knowledge; not captured in this Evidence Pack’s regulatory data |
| Predicted New Indication | Myofascial Pain Syndrome |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this Evidence Pack. Based on general pharmacological knowledge, morphine is a full agonist at the mu-opioid receptor and its efficacy in relieving moderate-to-severe nociceptive pain is well established; mechanistically, broad-spectrum opioid analgesia could plausibly extend to pain arising from myofascial trigger points, since both involve central and peripheral nociceptive signalling.
However, myofascial pain syndrome (MFPS) is a distinct clinical entity driven by localized muscle/fascial trigger points, muscle hyperirritability, and referred pain patterns — a pathophysiology that current first-line treatments (dry needling, trigger point injection, manual therapy, exercise) target directly, rather than through systemic opioid receptor blockade.
The evidence pack itself flags this limitation directly: the TxGNN score most likely reflects morphine’s general association with “pain” concepts in the knowledge graph rather than a disease-specific mechanistic link to MFPS. No identified clinical trial or publication tests morphine specifically as an MFPS therapy; the closest direct evidence is a single 2026 RCT using morphine as part of a peri-operative myofascial infiltration mixture, which is a narrow surgical-anaesthesia context rather than support for treating MFPS as a standalone condition.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06955923 | Phase 2 | Completed | 11 | Trigger point injections after total knee arthroplasty reduced pain scores/opioid use vs. sham; supports the MFPS-opioid interplay but did not test morphine directly. |
| NCT07413770 | NA | Recruiting | 60 | Classical massage (alone or with physiotherapy) evaluated for pain, muscle sensitivity, and quality of life in MFPS patients; non-pharmacological. |
| NCT05478928 | NA | Unknown | 60 | Compares invasive techniques (percutaneous microelectrolysis, dry needling) for myofascial trigger points using algometry; no opioid arm. |
| NCT04640896 | Phase 4 | Recruiting | 60 | Trigger point injections vs. traditional therapy for post-surgical cervical myofascial pain after anterior cervical surgery; non-opioid comparator. |
| NCT04684784 | NA | Completed | 46 | Dry needling effect on EMG activity at latent myofascial trigger points; no drug arm. |
| NCT03813485 | NA | Unknown | 24 | EMG comparison of dry needling at latent trigger points in tonic vs. phasic trapezius fibers; no drug arm. |
| NCT00580294 | NA | Completed | 12 | Pilot study of rapid rotation from morphine/oxycodone to oxymorphone; not MFPS-specific. |
| NCT01878019 | N/A | Completed | 92 | Naloxone (a morphine antagonist) used to probe brain pain responses in chronic pain patients; mechanistic tool study, not MFPS-specific. |
| NCT05069363 | NA | Recruiting | 20 | Feasibility trial of whole-body photobiomodulation for chronic pain; references morphine among current standard treatments but does not test it. |
| NCT06179199 | NA | Not yet recruiting | 40 | Evaluates tDCS analgesia in sedated ICU patients, citing side effects of excessive morphine use as rationale; not an MFPS trial. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41664327 | 2026 | RCT | Asian Spine Journal | Double-blind RCT comparing dexmedetomidine + morphine vs. plain ropivacaine for myofascial infiltration in thoracolumbar spinal fusion — the most direct morphine + myofascial evidence found, but limited to peri-operative infiltration. |
| 35066974 | 2022 | Cohort | Pain Practice | Retrospective cohort: a structured stretching program resolved myofascial pain and reduced opioid usage in “legacy pain” patients — an opioid-reduction outcome, not opioid efficacy evidence. |
| 22648287 | 2012 | Cohort | Journal of Anesthesia | Cervical facet joint injections added to a multimodal program improved long-standing cervical MFPS; opioids were not the primary intervention studied. |
| 21419546 | 2011 | Review | J Oral Maxillofac Surg | Reviews long-term opioid use in chronic temporomandibular joint dysfunction; evidence “neither supports nor refutes” opioid use in this myofascial-adjacent condition. |
| 39793344 | 2025 | Case series | Eur J Obstet Gynecol Reprod Biol | Pudendal nerve block after botulinum toxin injection for myofascial pelvic pain; no morphine arm. |
| 20390305 | 2010 | Observational | Schmerz | Altered pain thresholds during and after opioid withdrawal in chronic low back pain patients on long-term opioid therapy. |
| 16713811 | 2006 | Case series | J Oral Maxillofac Surg | TMJ arthrocentesis followed by intra-articular morphine infusion for refractory TMJ pain — direct morphine use, but in a TMJ/intra-articular context rather than systemic MFPS. |
| 17870625 | 2008 | RCT | European Journal of Pain | Compares epidural analgesia vs. intercostal cryoanalgesia for post-thoracotomy pain; morphine used as part of the epidural comparator regimen. |
| 21691691 | 2011 | Descriptive | Rev Assoc Med Bras | Descriptive study of therapeutic approaches in 56 patients with failed back surgery pain syndrome. |
| 9214190 | 1997 | Clinical study | Zh Nevrol Psikhiatr | Combined analgesic (caffetin) evaluated for acute cervicalgia/lumbar sciatica; not morphine-specific. |
South Africa Market Information
No SAHPRA registrations for Morphine are recorded in this Evidence Pack (market status: Not marketed, 0 licenses on file). This does not necessarily reflect real-world availability of morphine formulations in South Africa — it reflects a data gap in the source dataset used to build this pack (see Conclusion below).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale:
- No clinical trial or publication in this pack directly tests morphine as a treatment for myofascial pain syndrome; the strongest available evidence (a 2026 RCT) only covers morphine as part of a peri-operative infiltration mixture, not systemic MFPS management. Evidence level is L4 (mechanism/rationale only), and the underlying mechanistic link is judged weak — likely a broad “pain” association in the knowledge graph rather than an MFPS-specific effect.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings, contraindications) — currently a blocking data gap that prevents any safety (S1) evaluation
- Confirmed mechanism-of-action data from DrugBank or equivalent source
- A dedicated study of morphine (or an opioid class effect) specifically in an MFPS population, ideally against first-line non-opioid comparators (dry needling, trigger point injection, physiotherapy)
- Given morphine’s status as a controlled substance, a formal opioid risk-benefit assessment before considering use in a non-cancer, non-life-threatening chronic pain condition such as MFPS
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.